Gurgaon Samachar

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Perennial Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Perennial Allergic Rhinitis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Perennial Allergic Rhinitis Market

• The market size for Perennial Allergic Rhinitis in the leading markets is expected to increase during the forecast period 2026–2036.

• The growth of the Perennial Allergic Rhinitis market is expected to be primarily driven by increasing disease awareness and the launch of emerging therapies.

• According to DelveInsight’s analysis, the Perennial Allergic Rhinitis market is anticipated to increase during the forecast period (2026–2036), owing to the launch of emerging therapies and rising healthcare spending globally.

• It was found that allergic rhinitis is a common condition, affecting 10–30% of both children and adults in the United States. Approximately 40% of allergic rhinitis cases in the US are attributed to perennial allergic rhinitis.

• During childhood, males are more likely than females to experience perennial allergic rhinitis; however, this trend reverses in adulthood, with secondary research indicating that 54% of adult cases occur in females compared with 46% in males.

• According to the report, the United States accounted for more than 2.5 million diagnosed prevalent cases of Perennial Allergic Rhinitis in 2025 and is expected to witness a continuous increase throughout the forecast period.

• Among France and Germany, the most common allergy triggers identified were pollen (67.1%), house dust mites (65.2%), mold (51.6%), animals/fur (47.6%), and indoor plants (17.0%), highlighting the significant contribution of both seasonal and perennial indoor allergens.

• Leading Perennial Allergic Rhinitis companies, such as Eli Lilly, are advancing novel therapies that are expected to strengthen the treatment landscape over the coming years.

• The promising Perennial Allergic Rhinitis therapy in clinical development includes LY3650150 (lebrikizumab).

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/perennial-allergic-rhinitis-market

Key Factors Driving the Perennial Allergic Rhinitis Market

Increasing Exposure to Indoor Allergens: Growing urbanization, poor indoor ventilation, increased humidity, air pollution, and continuous exposure to dust mites, mold, pet dander, and cockroach allergens are contributing to the rising prevalence of perennial allergic rhinitis worldwide.

Growing Awareness and Improved Diagnosis: Greater awareness among patients and healthcare professionals, along with advances in allergy testing and improved diagnostic approaches, are leading to higher diagnosis rates and earlier treatment initiation.

Rising Adoption of Immunotherapy and Biologics: While antihistamines and intranasal corticosteroids remain the mainstay of treatment, allergen immunotherapy continues to gain acceptance as the only disease-modifying treatment. In addition, biologic therapies targeting key inflammatory pathways are expected to expand treatment options for patients with persistent disease.

Perennial Allergic Rhinitis Competitive Landscape

The treatment pipeline for Perennial Allergic Rhinitis remains relatively underdeveloped, with limited competition and few late-stage candidates. Eli Lilly is currently leading the emerging pipeline with LY3650150 (lebrikizumab).

LY3650150 (lebrikizumab) is a monoclonal antibody that selectively binds to interleukin-13 (IL-13) with high affinity, blocking downstream inflammatory signaling involved in allergic disease. The therapy is currently being evaluated in the Phase III PREPARED-1 trial for perennial allergen-induced allergic rhinitis and has the potential to address unmet needs in patients with persistent symptoms inadequately controlled by conventional therapies.

Discover more about therapies set to grab major Perennial Allergic Rhinitis market share @ Perennial Allergic Rhinitis Treatment Landscape

Recent Developments in the Perennial Allergic Rhinitis Market

• Eli Lilly is advancing LY3650150 (lebrikizumab) as a novel biologic therapy for perennial allergic rhinitis.

• LY3650150 (lebrikizumab) is currently being evaluated in the Phase III PREPARED-1 clinical trial for patients with perennial allergen-induced allergic rhinitis.

• The primary completion date for the PREPARED-1 study is expected in September 2026.

• The report highlights that the perennial allergic rhinitis pipeline remains underdeveloped, creating significant opportunities for innovative and disease-modifying therapies to enter the market.

What is Perennial Allergic Rhinitis?

Perennial Allergic Rhinitis is a chronic inflammatory disorder of the nasal passages caused by year-round exposure to indoor allergens such as dust mites, pet dander, mold, and cockroach particles. Unlike seasonal allergic rhinitis, symptoms persist throughout the year and commonly include nasal congestion, sneezing, rhinorrhea, nasal itching, postnasal drip, facial pressure, and sleep disturbances. Diagnosis typically involves clinical history, physical examination, and allergy testing using skin or blood tests. Current management focuses on allergen avoidance, antihistamines, intranasal corticosteroids, decongestants, and allergen immunotherapy, while biologic therapies such as IL-13 inhibitors are emerging as promising treatment options for patients with inadequately controlled disease.

Perennial Allergic Rhinitis Epidemiology Segmentation

The Perennial Allergic Rhinitis epidemiology section provides insights into the historical and current Perennial Allergic Rhinitis patient pool and forecasted trends for the leading markets. The Perennial Allergic Rhinitis market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalent Cases of Allergic Rhinitis

• Total Diagnosed Prevalent Cases of Allergic Rhinitis

• Total Diagnosed Prevalent Cases of Perennial Allergic Rhinitis

• Gender-specific Diagnosed Prevalent Cases of Perennial Allergic Rhinitis

• Allergen-specific Diagnosed Prevalent Cases of Perennial Allergic Rhinitis

• Treated Cases of Perennial Allergic Rhinitis

Scope of the Perennial Allergic Rhinitis Market Report

• Therapeutic Assessment: Perennial Allergic Rhinitis current marketed and emerging therapies

• Perennial Allergic Rhinitis Market Dynamics: Key Market Forecast Assumptions of Emerging Perennial Allergic Rhinitis Therapies and Market Outlook

• Key Companies: Eli Lilly and others

• Key Therapies: LY3650150 (lebrikizumab), Intranasal Corticosteroids, Antihistamines, Decongestants, Immunotherapy, and others

• Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

• Unmet Needs, KOL’s Views, Analyst’s Views, Perennial Allergic Rhinitis Market Access and Reimbursement

To know more about Perennial Allergic Rhinitis companies working in the treatment market, visit @ Perennial Allergic Rhinitis Clinical Trials and Therapeutic Assessment

Table of Contents

• Perennial Allergic Rhinitis Market Report Introduction

• Executive Summary for Perennial Allergic Rhinitis

• Key Events

• Perennial Allergic Rhinitis Market Overview at a Glance

• Market Share (%) Distribution of Perennial Allergic Rhinitis by Therapies

• Methodology of Epidemiology and Market

• Perennial Allergic Rhinitis Disease Background and Overview

• Signs and Symptoms

• Causes

• Related Conditions

• Etiology

• Risk Factors

• Pathophysiology

• Complications

• Diagnosis

• Diagnostic Algorithm

• Diagnostic Guidelines

• Management and Treatment

• Treatment Algorithm

• Treatment Guidelines

• Perennial Allergic Rhinitis Epidemiology and Patient Population

• Country-Specific Patient Population of Perennial Allergic Rhinitis

• Patient Journey

• Emerging Drugs

• LY3650150 (lebrikizumab): Eli Lilly

• Perennial Allergic Rhinitis Market Analysis

• Market Outlook

• Attribute Analysis

• Pricing Trends

• Launch Year and Therapy Uptake

• Country-Wise Perennial Allergic Rhinitis Market Analysis (2022–2036)

• Market Access and Reimbursement

• KOL Views

• SWOT Analysis

• Perennial Allergic Rhinitis Unmet Needs

• Perennial Allergic Rhinitis Appendix

• Perennial Allergic Rhinitis Report Methodology

• DelveInsight Capabilities

• Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/